Your browser doesn't support javascript.
loading
Survival benefit of liver transplantation utilizing marginal donor organ according to ABO blood type.
Akabane, Miho; Bekki, Yuki; Inaba, Yosuke; Imaoka, Yuki; Esquivel, Carlos O; Kwong, Allison; Kim, W Ray; Sasaki, Kazunari.
Afiliação
  • Akabane M; Division of Abdominal Transplant, Department of Surgery, Stanford University Medical Center, Stanford, California, USA.
  • Bekki Y; Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Inaba Y; Clinical Research Promotion Center, The University of Tokyo Hospital, Tokyo, Japan.
  • Imaoka Y; Division of Abdominal Transplant, Department of Surgery, Stanford University Medical Center, Stanford, California, USA.
  • Esquivel CO; Division of Abdominal Transplant, Department of Surgery, Stanford University Medical Center, Stanford, California, USA.
  • Kwong A; Division of Gastroenterology and Hepatology, Stanford University Medical Center, Stanford, California, USA.
  • Kim WR; Division of Gastroenterology and Hepatology, Stanford University Medical Center, Stanford, California, USA.
  • Sasaki K; Division of Abdominal Transplant, Department of Surgery, Stanford University Medical Center, Stanford, California, USA.
Liver Transpl ; 2024 Sep 18.
Article em En | MEDLINE | ID: mdl-39287561
ABSTRACT

BACKGROUND:

The current liver transplantation (LT) allocation policy focuses on the Model for End-Stage Liver Disease (MELD) scores, often overlooking factors like blood type and survival benefits. Understanding blood types' impact on survival benefits is crucial for optimizing the MELD 3.0 classification.

METHOD:

This study used the United Network for Organ Sharing national registry database (2003-2020) to identify LT characteristics per ABO blood type and to determine the optimal MELD 3.0 scores for each blood type, based on survival benefits.

RESULTS:

The study included LT candidates aged 18 years or older listed for LT (total N=150,815; A56,546, AB5,841, B18,500, O69,928). Among these, 87,409 individuals (58.0%) underwent LT (A32,156, AB4,362, B11,786, O39,105). Higher transplantation rates were observed in AB and B groups, with lower median MELD 3.0 scores at transplantation (AB21, B24 vs. A/O26, p<0.01) and shorter waiting times (AB101 days, B172 days vs. A211 days, O201 days, p<0.01). A preference for Donation after Cardiac Death (DCD) was seen in A and O recipients. Survival benefit analysis indicated that B blood type required higher MELD 3.0 scores for transplantation than A and O (Donation after Brain Death transplantation ≥15 in B vs. ≥11 in A/O; DCD transplantation ≥21 in B vs. ≥11 in A, ≥15 in O).

CONCLUSION:

The study suggests revising the allocation policy to consider blood type for improved post-LT survival. This calls for personalized LT policies, recommending higher MELD 3.0 thresholds, particularly for individuals with type B blood.

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article